Eye drops slow nearsightedness progression in kids, study finds
The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon. The three-year… read more.
The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon. The three-year… read more.
– Primary results of the FROZEN-AF IDE trial with the POLARx Cryoablation System : Results from the global, prospective, non-randomized, single-arm FROZEN-AF IDE study of the POLARx Cryoablation… read more.
Clinician burnout and overwork are known to adversely affect patient safety and junior doctors may be particularly vulnerable, research suggests. The UK is facing a crisis in recruitment and retention… read more.
Ketamine taken in the form of a nasal spray may prove a safe and effective treatment for refractory chronic migraine, suggests a single centre study, published in the… read more.
Lexicon Pharmaceuticals, Inc. announced that the FDA has approved Inpefa (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent… read more.
Cancer patients who continue smoking after their diagnosis have a nearly doubled risk of heart attack, stroke or death due to cardiovascular disease compared with non-smokers, according to… read more.
While it can take years for the pharmaceutical industry to create medicines capable of treating or curing human disease, a new study suggests that using generative artificial intelligence… read more.
Takeda announced that the FDA has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary immunodeficiency (PI) in children 2-16 years… read more.
How do you diagnose and manage depression in adolescents? A new review published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.220966 aims to help primary care clinicians address this increasingly common, yet under-detected… read more.
Research into new drug development is ongoing at a very fast pace globally. In keeping with newer remedies entering the market, there is a need for optimizing existing… read more.
AbbVie announced the European Commission (EC) approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK)… read more.
Engineers at the University of California San Diego have developed a simple, low-cost clip that uses a smartphone’s camera and flash to monitor blood pressure at the user’s… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.